ARTICLE | Top Story

Anthem picks Harvoni

January 9, 2015 3:05 AM UTC

Anthem Inc. (NYSE:ANTM) said Thursday it would make Harvoni ledipasvir/ sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD) its preferred drug to treat HCV across its employer-based plans.

The payer said Harvoni would have Tier 3 or Tier 4 status on these plans and that members would still have access to other HCV medicines, including Viekira Pak from AbbVie Inc. (NYSE:ABBV) in the case of medical exceptions. Tier 3 or Tier 4 drugs typically require co-insurance where the member pays some proportion of the total drug cost, though Anthem didn't disclose the level of cost-sharing for Harvoni. ...